Suppr超能文献

p38丝裂原活化蛋白激酶抑制的树突状细胞可诱导更强的抗肿瘤免疫反应并克服调节性T细胞介导的免疫抑制。

p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.

作者信息

Lu Yong, Zhang Mingjun, Wang Siqing, Hong Bangxing, Wang Zhiqiang, Li Haiyan, Zheng Yuhuan, Yang Jing, Davis Richard E, Qian Jianfei, Hou Jian, Yi Qing

机构信息

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

Institute of Translational Medicine, The First Hospital, Jilin University, Changchun 130061, China.

出版信息

Nat Commun. 2014 Jun 24;5:4229. doi: 10.1038/ncomms5229.

Abstract

Dendritic cell (DC)-based cancer immunotherapy is a promising method, but so far has demonstrated limited clinical benefits. Regulatory T cells (Tregs) represent a major obstacle to cancer immunotherapy approaches. Here we show that inhibiting p38 MAPK during DC differentiation enables DCs to activate tumour-specific effector T cells (Teff), inhibiting the conversion of Treg and compromising Treg inhibitory effects on Teff. Inhibition of p38 MAPK in DCs lowers expression of PPARγ, activating p50 and upregulating OX40L expression in DCs. OX40L/OX40 interactions between DCs and Teff and/or Treg are critical for priming effective and therapeutic antitumour responses. Similarly, p38 MAPK inhibition also augments the T-cell stimulatory capacity of human monocyte-derived DCs in the presence of Treg. These findings contribute to ongoing efforts to improve DC-based immunotherapy in human cancers.

摘要

基于树突状细胞(DC)的癌症免疫疗法是一种很有前景的方法,但迄今为止临床疗效有限。调节性T细胞(Tregs)是癌症免疫治疗方法的主要障碍。在这里,我们表明在DC分化过程中抑制p38丝裂原活化蛋白激酶(MAPK)可使DC激活肿瘤特异性效应T细胞(Teff),抑制Treg的转化并削弱Treg对Teff的抑制作用。DC中p38 MAPK的抑制降低了PPARγ的表达,激活了p50并上调了DC中OX40L的表达。DC与Teff和/或Treg之间的OX40L/OX40相互作用对于引发有效的治疗性抗肿瘤反应至关重要。同样,在存在Treg的情况下,p38 MAPK抑制也增强了人单核细胞衍生DC的T细胞刺激能力。这些发现有助于持续努力改善人类癌症中基于DC的免疫疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ae/4249595/b32921132ddc/nihms643441f1.jpg

相似文献

引用本文的文献

2
Landscape of targeted therapies for lung squamous cell carcinoma.肺鳞状细胞癌的靶向治疗概况
Front Oncol. 2024 Oct 31;14:1467898. doi: 10.3389/fonc.2024.1467898. eCollection 2024.
3
The mARS complex: a critical mediator of immune regulation and homeostasis.mARS 复合物:免疫调节和稳态的关键介质。
Front Immunol. 2024 Jun 21;15:1423510. doi: 10.3389/fimmu.2024.1423510. eCollection 2024.

本文引用的文献

5
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.OX40、4-1BB 和 CD40 作为癌症免疫治疗的靶点。
Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14.
6
SnapShot: p38 MAPK signaling.简讯:p38丝裂原活化蛋白激酶信号传导
Cell. 2013 Jan 31;152(3):656-656.e1. doi: 10.1016/j.cell.2013.01.029.
10
Targeting regulatory T cells in cancer.靶向肿瘤中的调节性 T 细胞。
Cancer Res. 2011 Nov 15;71(22):6915-20. doi: 10.1158/0008-5472.CAN-11-1156. Epub 2011 Nov 8.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验